Abstract
The objective of this study was to evaluate the safety and efficacy of the humanized antibody ATM-027 in a baseline versus treatment magnetic resonance imaging-monitored study. Expansion of Vbeta5.2/5.3(+) T cells has been demonstrated in the peripheral blood, cerebrospinal fluid, and brain lesions of MS patients. In a phase I study, ATM-027 depleted these cells in peripheral blood and, in parallel, T-cell MBP reactivity and IFN-gamma expression were reduced. We studied 59 patients with relapsing-remitting MS (47 on ATM-027 and 12 on placebo) stratified for HLA-DR2 status. Monthly intravenous injections were given for 6 months. Individual dose titration was employed to obtain depletion of the target T-cell level and downregulation of antigen receptor density as monitored by flow cytometry. Five monthly magnetic resonance imaging scans were performed before treatment to establish baseline activity, six during treatment, and three during follow-up. Additional immunological assessments were performed to elucidate the mechanism of action of ATM-027. The treatment was safe and well tolerated, inducing consistent suppression of the target cell population. During run-in, active lesions were found in 78.7% (37/47) of patients treated w...Continue Reading
References
Jan 1, 1992·Annual Review of Immunology·R MartinD E McFarlin
Sep 1, 1990·The Journal of Clinical Investigation·T OlssonH Link
Oct 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·B L KotzinA A Vandenbark
May 1, 1990·European Journal of Immunology·L KabilanM Troye-Blomberg
Nov 1, 1983·Neurology·J F Kurtzke
Mar 1, 1983·Annals of Neurology·C M PoserW W Tourtellotte
Sep 23, 1995·Lancet·R MedaerJ Zhang
Apr 1, 1995·Immunological Reviews·T Olsson
Mar 4, 1993·Nature·J R OksenbergL Steinman
Sep 10, 1993·Science·J ZhangJ Raus
Sep 1, 1994·Annals of Neurology·J LinkH Link
Oct 1, 1996·Nature Medicine·A A VandenbarkH Offner
Oct 29, 1996·Proceedings of the National Academy of Sciences of the United States of America·P MusetteD Dormont
May 1, 1997·The Journal of Clinical Investigation·M H RepR A van Lier
Aug 1, 1997·Neurology·B W van OostenC H Polman
Dec 31, 1997·Neurology·F BarkhofH J Adèr
Jun 17, 1998·Journal of Neuroimmunology·B GranL Massacesi
Sep 11, 1999·Annals of Neurology·A J ColesA Compston
Sep 28, 1999·Current Opinion in Neurology·G Martino, H P Hartung
Oct 16, 1999·Journal of Neurology, Neurosurgery, and Psychiatry·R N HeardG J Stewart
Nov 24, 1999·Lancet·A J ColesA Compston
Dec 30, 1999·International Reviews of Immunology·H Offner, A A Vandenbark
Oct 4, 2000·Nature Medicine·B BielekovaR Martin
Oct 4, 2000·Nature Medicine·L KapposL Steinman
May 1, 1995·Molecular Medicine Today·L SteinmanD Altmann
Citations
Sep 18, 2004·British Journal of Clinical Pharmacology·Per-Henrik ZingmarkMats O Karlsson
Aug 26, 2006·Nature Clinical Practice. Neurology·Reinhard Hohlfeld, Hartmut Wekerle
Jun 7, 2007·Der Nervenarzt·C KleinschnitzH Wiendl
Mar 5, 2011·British Journal of Pharmacology·Cris S ConstantinescuBruno Gran
Apr 23, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yoh MatsumotoYasuto Itoyama
Jan 22, 2005·Annual Review of Medicine·Jingwu Zhang, George Hutton
Oct 4, 2002·The New England Journal of Medicine·Joep Killestein
Mar 18, 2005·Annual Review of Immunology·Mireia Sospedra, Roland Martin
Dec 7, 2011·Nature Reviews. Neurology·Frederik BarkhofMassimo Filippi
Apr 29, 2014·Immunologic Research·Lawrence Steinman
Aug 13, 2004·Proceedings of the National Academy of Sciences of the United States of America·Reinhard Hohlfeld, Hartmut Wekerle
Feb 22, 2003·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Stephen R RobinsonGerald Münch
Apr 2, 2019·Journal of Neuroimmunology·Simon SchliffkeMascha Binder
Feb 21, 2004·Journal of Neuroimmunology·Sarah FlorisJan F Meilof
Jul 21, 2004·Journal of the Neurological Sciences·R E Gonsette
Sep 3, 2004·Journal of Neuroimmunology·M H J VogtL Nagelkerken